SORT BY

The Future 50

Courtesy of Regeneron Pharmaceuticals
leaders

10

Regeneron Pharmaceuticals

REGN

Investors are betting big on ­Regeneron: Its market value has jumped by more than a fifth in 2017. Why? Sales of eye-­disease treatment Eylea are strong. The company’s expansive pipeline could continue to fuel steady growth. Regeneron has 11 experimental treatments in Phase II or Phase III clinical trials. One that could prove critical is REGN2810, a type of next-generation medicine currently in late-stage studies that harnesses the body’s immune system to fight cancer.

Looking for leads, investment insights, or competitive intelligence?

Overall Score

2.5

Sector

Health Care

Industry

Pharmaceuticals

CEO

Leonard S. Schleifer

Employees

5,400

HQ Location

Tarrytown, N.Y.

Revenues ($M) (Past 12 Months)

$5,236

Profits ($M) (Past 12 Months)

$1,155

Market Value as of Oct. 9, 2017 ($M)

$50,054

Revenue and net income for 12 months ended June 30, 2017. Source: S&P Global.
Regeneron Pharmaceuticals is also featured in these fortune lists

News about Regeneron Pharmaceuticals

Could a Vaccine Prevent High Cholesterol and Heart Disease?

Scientists are ready to move an experimental treatment into phase 1 trials.

Read More →
Trump's Proposed Science Cuts Could Devastate Future Generations, Pharma Expert Says

“We should only be working on two things, health and the freaking environment.”

Read More →
Pharma Executives Aren't Excited About Trump's Plans to Ease FDA Regulation

They say a robust review process is needed to convince doctors and insurers new drugs have value.

Read More →